Category Archives: Immuno-Oncology

Alternative Cancer Treatment, Cancer Research, Immuno-Oncology, Immunotherapy, News

What’s Happening in Immunotherapy Research – Part One

What's New in Immunotherapy
What’s New in Immunotherapy

As immunotherapy for cancer continues to gain traction in the medical community, researchers around the globe are directing their efforts toward finding new treatment methods and improving existing ones. Here’s a look at some of the exciting developments in immunotherapy treatments that are making news today.

Refining Monoclonal Antibodies

Monoclonal antibodies, or mAbs, are proteins that take advantage of the difference between cancer cells and normal cells. Scientists are exploring ways to make mAbs even more powerful, such as attaching them to drugs or other substances, while making them less likely to trigger an immune response. They are also working on combining mAbs for a more focused attack on tumors.

CAR T-Cells

T-cells, which are part of the immune system, have long been a major subject of immunotherapy research. Recent trials involve removing T-cells from a patient, genetically adding CARs (chimeric antigen receptors), then returning them to the patient’s blood, where they can more precisely target cancer cells. This method has shown particularly promising results in cases featuring advanced forms of leukemia and lymphoma.

Tumor-Infiltrating Lymphocytes

Another approach using T-cells centers on tumor-infiltrating lymphocytes (TILs) found deep within tumors. The TILs are removed from tumor samples and treated with interleukin-2 so they multiply rapidly. Once injected back into the patient, the TILs are better equipped to fight cancer cells.

Issels®: A Pioneer in Immunotherapy Treatments

In our next post, we’ll continue our look at the latest updates on research centering on immunotherapy for cancer. Contact us to learn more about how Issels® has been a leader in personalized, non-toxic immunotherapy protocols.

Alternative Cancer Treatment, Cancer Research, Immuno-Oncology, Immunotherapy

Higher Genetic Mistakes in Tumors May Predict a Better Result for Immunotherapy Treatment

Immunotherapy Can Expand Options for Those With Limited Cancer Treatment Options
Immunotherapy Can Expand Options for Those With Limited Cancer Treatment Options

For many patients with difficult-to-treat tumors, immunotherapy for cancer has successfully expanded their previously limited options. According to a study recently presented at the American Society of Clinical Oncology conference, a new immunotherapy drug has shown promise for treatment of advanced bladder cancer.

The Power of Checkpoint Inhibitors

Researchers speaking at the ASCO conference in Chicago last June reported on the results of clinical trials for atezolizumab, marketed under the name Tecentriq. Atezolizumab is one of a growing number of treatments referred to as checkpoint inhibitors.

Cancer cells often get a foothold by flying under the radar of immune cells, which are your body’s main line of defense against bacteria, viruses and other “invaders.” Checkpoint inhibitors target a molecule called PD-L1, thereby releasing immune cells to attack and kill the rogue cancer cells.

Tumors with “High Mutational Burden” Respond to Immunotherapy

A follow-up analysis to the bladder cancer trials indicated that tumors with a “high mutational burden,” which refers to the number of genetic faults in the cells, appear to be more receptive to immunotherapy. Dr. Jonathan Rosenburg of the Memorial Sloan Kettering Cancer Center in NYC explained that it was made easier for the immune system to identify the mutated cells in such tumors.

Issels®: A Leader in Immunotherapy for Cancer

Our state-of-the-art non-toxic immunotherapy treatments have been used successfully on patients with all forms of cancer, including bladder, breast and melanoma. Visit our website to learn more about our cancer vaccines, gene-targeted therapies and other protocols individually designed to address your specific needs.

Alternative Cancer Treatment, Cancer Research, Immuno-Oncology, Immunotherapy

Pancreatic Cancer: Hijacking the Immune System to Hide Its Growth

Pancreatic Cancer: Hijacking the Immune System to Hide Its Growth
Pancreatic Cancer: Hijacking the Immune System to Hide Its Growth

With a five-year survival rate of only three percent, pancreatic cancer is one of the more difficult types of cancer to treat. Scientists from Cancer Research UK, in collaboration with scientists from pharmaceutical giant AstraZeneca, recently announced their discovery of a promising method to help defeat these tumors.

Pancreatic Cancer’s “Stealth Attack”

The immune system is your body’s first line of defense against cancer cells and other foreign bodies that threaten your health. In the case of pancreatic cancer, once the cells make it past the initial gauntlet, they move on to hijack parts of the immune system to facilitate their growth.

The UK study, published in Cancer Cell, reported the team’s discovery of CXCR2, which is a protein that serves as the gatekeeper for pancreatic tumors, guarding them from attack by immune cells. Use of an experimental drug that blocks CXCR2 allowed T-cells to enter the tumor, making it more vulnerable to treatment.

Immunotherapy for Pancreatic Cancer

Until now, the shielding process has made pancreatic cancer particularly resistant to immunotherapy. Professor Peter Johnson, chief clinician at Cancer Research UK, said their study suggests that using the new drug in concert with immunotherapy treatments could create “a powerful weapon” in the fight against pancreatic cancer.

Using the Body’s Natural Defenses to Defeat Cancer

For more than 60 years, our Issels® center has been the leader in the use of immunotherapy for pancreatic cancer and many other types. Contact us today for more information about our personalized non-toxic treatments, including cancer vaccines, hyperthermia and gene-targeted therapies.

Cancer Care Tips, Immuno-Oncology, News

July is Bladder Cancer Awareness Month – Do You Know the Bladder Cancer Risk Factors?

Men Are More Likely to Get Bladder Cancer Than Women... Are You at Risk?
Men Are More Likely to Get Bladder Cancer Than Women… Are You at Risk?

This July, you may see people sporting a yellow ribbon for Bladder Cancer Awareness Month. What do you know about the risks for this type of cancer that accounts for five percent of all new diagnoses in the United States each year?

Demographic Factors

  • Bladder cancer is the fourth most common type of cancer in men. According to projections by the American Cancer Society, in 2016 new diagnoses of bladder cancer in men will outnumber women three to one.
  • Approximately 90 percent of bladder cancer occurs in people over the age of 55.
  • Caucasians are twice as likely as African-Americans and Hispanics to develop bladder cancer. Occurrences are also lower in Asian-Americans and American Indians.

Lifestyle Factors

  • Smoking is the most serious risk factor, tripling your chances of developing bladder cancer. In addition, roughly half of all bladder cancer cases with both men and women are caused by smoking.
  • The diabetes medicine Actos, along with certain dietary supplements, has been linked to an increased risk of bladder cancer.

Medical Factors

  • Previous chemotherapy or radiation treatment can increase your risk of developing bladder cancer.
  • While direct cause-and-effect of bladder cancer has not yet been established, a link has been found with chronic urinary tract infections or bladder and kidney stones.

Issels® Offers Non-Toxic Immunotherapy for Bladder Cancer

Patients at Issels® have been successfully treated with immunotherapy for bladder cancer as well as other common forms such as lung cancer, breast cancer and melanoma. Contact us to learn more about our cancer vaccines and other personalized, integrative treatment programs.

Alternative Cancer Treatment, Cancer Research, Immuno-Oncology, Immunotherapy, News

July is Bladder Cancer Awareness Month, Will You Be Wearing the Yellow Ribbon?

1 Comment
New Immunotherapy Drug Can Help Fight Bladder Cancer
New Immunotherapy Drug Can Help Fight Bladder Cancer

If you or someone you love has received a diagnosis of bladder cancer or is in stage four and have exhausted treatment options, NBC news reports that there may be new hope for immunotherapy treatment for bladder cancer. This information is timely as July is Bladder Cancer Awareness Month.

Immunotherapy treatments

Immunotherapy for bladder cancer works by treating a person’s immune system so it has the ability to fight cancer.

According to the NBC news article, “more successful approaches, involve training immune cells to recognize a patient’s specific tumors, or finding and amplifying a patient’s own tumor-specific immune cells.” Immunotherapy now appears to be the best course of cancer treatment for many patients.

New drug, new hope

Hope now lies in a drug newly-approved by the FDA called atezolizumab (brand name Tecentriq) that boosts the immune system to slow the spread of tumors in patients in the advanced stages of bladder cancer. It’s the latest development in immunotherapy for bladder cancer treatments and it has shown promising results.

In a study of 119 patients who received the drug as treatment revealed that growth stopped in the tumors in 24% of those patients in the advanced stages of bladder cancer. The drug also shrank the tumors by 30%. According to the research team, 21 of the original patients from 2014 who received the immunotherapy for bladder cancer are still in remission today.

Learn more about our non-toxic immunotherapy for bladder cancer by contacting Issels® Integrative Immuno-Oncology.

Alternative Cancer Treatment, Cancer Survivors, Immuno-Oncology, Immunotherapy, Living with Cancer

Cancer Survivors: A Unique Perspective on Hope

Cancer Survivors: A Unique Perspective on Hope
Cancer Survivors: A Unique Perspective on Hope

Here at Issels®, we frequently encounter people who have been newly diagnosed with cancer, and their hope for a long healthy life seems gone. For the longest time, a cancer diagnosis has been linked with impending death, and while it’s true that some do lose their lives to this terrible disease, for the first time cancer patients can truly have hope.

There have been many advances in cancer treatment in recent years, and more patients are getting screened early on if they feel they are at higher risk. Early detections and improvements in treatment are saving lives, and the number of cancer survivors is expected to increase at an incredible rate in the months and years ahead. Currently, there are 15.5 million cancer survivors in the United States, and in just ten years that number is expected to hit 20 million.

Knowing these numbers is important, because cancer survivors have different needs than cancer patients; especially those who have undergone treatments such as chemotherapy and radiation. These patients often have serious, long-standing effects from what we’ve always thought of as “conventional” cancer treatments, and experts are still trying to find a way to help them with the physiological and psychological effects that can last the rest of their lives.

There’s no question that chemotherapy and radiation have been life-saving for many cancer survivors. However, they have also caused significant problems, such as heart disease, osteoporosis, neuropathy, and other physical ailments.

At Issels®, our focus is on immunotherapy, which has been shown to have no devastating long-term effects. Please contact us to learn more about this breakthrough in cancer treatment.